Trial Profile
PET Imaging of [18F]Dabrafenib Distribution and Kinetics in Brain Metastasis in Patients With BRAF Positive Metastastic Melanoma. A Feasibility Study.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Pharmacokinetics
- 04 May 2020 Status changed from recruiting to discontinued.
- 23 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 23 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.